Turn on Your Bio-Engine – Increasing the Profitability of Your Biogas Process

Understanding the biology of your therapeutic is key to effectively and efficiently progressing it from first principles, through safety assessment studies, and into clinical trials. The unique characteristics and specific biology of each large molecule therapeutic make it impossible to design a “one size fits all” approach to non-clinical development, requiring instead a design tailored to each molecule. For efficient development strategies, this should include a thorough understanding of the disease and therapeutic biology as well as ensuring that the most appropriate studies are conducted to progress each molecule. Despite the need for unique approaches for each novel biologic, there are seven key steps that should be considered when developing biologics through non-clinical development in order to ensure effective and efficient progress.

Maize is one of the most economically important crops globally and much effort has been spent generating the high quality B73 reference genome. However, the 10 chromosome, 2.3 gigabase (Gb) B73 reference genome was a substantial challenge due to the fact it is comprised of 85% transposable elements, 75% of which are long terminal repeat (LTR) retrotransposons that share high sequence similarity and form nested repeat structures. Ultralong Oxford Nanopore Technology (ONT) holds the promise of traversing the complex repeat structures of maize and enabling rapid sequencing of new breeding lines.

Cell-mediated immunotherapies are an emerging modality that can revolutionize cancer research as well as the study of the immune system. However, establishing standardization and scalability for necessary bioanalytics into product release practices are hampered by two major challenges

The Webinar will focus on how health sciences are becoming more democratized and decentralized, hacking biotechnology investments is getting more accessible, obvious, and transparent. Investing in biotech is no longer reserved for specialized VCs and funds with deep pockets. This one hour webinar will discuss finding the right opportunities in responsible healthcare investing, focusing on investing in biotech companies.